CytomX Therapeutics CTMX Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's change in deferred revenue?
- CytomX Therapeutics (CTMX) reported change in deferred revenue of -$9.61M in Q1 2026.
- How has CytomX Therapeutics's change in deferred revenue changed year-over-year?
- CytomX Therapeutics's change in deferred revenue increased by 78.5% year-over-year, from -$44.62M to -$9.61M.
- What is the long-term trend for CytomX Therapeutics's change in deferred revenue?
- Over 4 years (2021 to 2025), CytomX Therapeutics's change in deferred revenue has grown at a 18.1% compound annual growth rate (CAGR), from -$33.95M to -$66.15M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.